1. Home
  2. STRO vs VYGR Comparison

STRO vs VYGR Comparison

Compare STRO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$11.64

Market Cap

85.0M

Sector

Health Care

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.92

Market Cap

226.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRO
VYGR
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.0M
226.8M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
STRO
VYGR
Price
$11.64
$3.92
Analyst Decision
Hold
Strong Buy
Analyst Count
8
6
Target Price
$18.29
$17.00
AVG Volume (30 Days)
129.5K
432.5K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$105,646,000.00
$31,316,000.00
Revenue This Year
$63.08
N/A
Revenue Next Year
N/A
$71.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.23
$2.65
52 Week High
$21.50
$6.27

Technical Indicators

Market Signals
Indicator
STRO
VYGR
Relative Strength Index (RSI) 79.57 41.18
Support Level $8.49 $3.93
Resistance Level $12.00 $4.26
Average True Range (ATR) 0.86 0.21
MACD -0.02 -0.03
Stochastic Oscillator 85.95 0.75

Price Performance

Historical Comparison
STRO
VYGR

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: